[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cartilage-damage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cartilage-damage":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,43,69,103,135,157,190],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100630722","phase-4-pilot-exploration-of-platelet-characterization-of-platelet-rich-plasma-created-by-two-different-systems-100630722",false,"NCT07491367","Pilot Exploration of Platelet Characterization of Platelet Rich Plasma Created by Two Different Systems","PRP-PEPC","Inclusion Criteria:\n\n* Kellgren-Lawrence (KL) Grade 1-3 knee osteoarthritis\n* Symptoms of knee osteoarthritis for at least 3 months before presentation in one knee\n* Will be able to attend and perform physical therapy\n\nExclusion Criteria:\n\n* Received injection therapy for knee osteoarthritis in the past 6 months\n* Have severe arthritis diagnosed in ≥1 major joint by radiology criteria\n* History of septic arthritis\n* Underwent knee surgery for osteoarthritis or osteochondral defects within 1 year before randomization (e.g., autograft or allograft surgery)\n* Have had high tibial osteotomy, partial knee replacement, patellar resurfacing, total knee replacement, or have existing surgical hardware in the knee\n* Received a platelet-rich plasma injection elsewhere in the body within the past 3 months\n* Have a platelet disorder or bleeding disorder\n* Have a rheumatologic disease, autoimmune disorder, immunocompromised status, or active history of cancer\n* Are taking chemotherapy, require regular prednisone, or require regular anti-inflammatory use\n* Are pregnant, breastfeeding, or unwilling to practice birth control during the study\n* If both knees have osteoarthritis and the other knee has KL score equal to or greater than 2.\n* Have uncontrolled illness, physical disability, or other contraindication to aerobic exercise training","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The investigators would like to study the differences in the quality of Platelet Rich Plasma (PRP) between two different machines in those with knee osteoarthritis. Knee osteoarthritis means your cartilage has been worn down, and it affects your knee joint. Both machines, the APEX Biologix XCELL PRP System and the Emcyte PurePRP Supraphysiologic Concentrating System, are FDA approved, commercially available, and makes PRP. The investigators will check if the platelets in the PRP have different amounts or work differently. The investigators will also assess participants symptoms after the injection and compare the two different preparation systems.",[26,27,28,29],"Knee Osteoarthristis","Cartilage Damage","Platelet Rich Plasma","Platelet Rich Plasma Injection","NOT_YET_RECRUITING","2026-06-08",{"date":33,"type":34},"2026-06-09","ACTUAL",{"date":36,"type":20},"2026-07-01",{"date":38,"type":20},"2028-09",{"name":40,"class":41},"University of California, San Francisco","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100618976","point-of-care-ultrasound-pocus-for-diagnosis-and-treatment-of-fractures-in-the-costal-cartilage-100618976","NCT07338617","Point of Care Ultrasound (POCUS) for Diagnosis and Treatment of Fractures in the Costal Cartilage","Inclusion Criteria:\n\n* Trauma patients (≥18 years) treated at the Department of Surgery, Sahlgrenska University Hospital, where CT has shown at least one recent injury to the chest wall.\n\nExclusion Criteria:\n\n* Patients with injuries resulting from CPR, severe head injury, spinal injury, and neurological or musculoskeletal disease affecting chest mobility will be excluded.",{"count":50,"type":20},100,"OBSERVATIONAL","The goal of this observational study is to learn if combining ultrasound and CT scans can better diagnose cartilage fractures in the ribs, and to understand how finding these injuries affects treatment decisions for patients with injuries to the Chest wall.\n\nThe main questions it aims to answer are:\n\n* Does using both ultrasound and CT scans find more costal cartilage fractures than CT scans alone?\n* Does discovering costal cartilage fractures change how patients are treated, such as whether more patients receive surgery or if different fractures are repaired?\n* How do costal cartilage fractures heal, and do they affect lung function, pain, or the risk of complications after surgery?\n\nPatients with cartilage injuries will be followed up at 1, 3, and 12 months after their injury. They will be checked for pain, instability, and healing using ultrasound and sometimes CT scans. The study will also assess lung function, quality of life, and pain levels.",[54,27],"Rib Fracture",[56,57,58,59],"Rib Fractures","Fractures, Cartilage","Ultrasonography","Traumatology","2026-04-27",{"date":62,"type":34},"2026-04-28",{"date":64,"type":20},"2026-06",{"date":66,"type":20},"2028-01",{"name":68,"class":41},"Sahlgrenska University Hospital",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":5},"100591539","phase-1-safety-and-efficacy-of-huc-msc-for-the-treatment-of-cartilage-damage-in-the-knee-joint-100591539","NCT06981741","Safety and Efficacy of hUC-MSC for the Treatment of Cartilage Damage in the Knee Joint","Phase I\u002FIIa Study to Test the Safety and Efficacy of MSC From Umbilical Cord Tissue (UC-MSC) for the Treatment of Cartilage Damage in the Knee Joint","BPCC001","Inclusion Criteria:\n\n* Patients of any gender with an age from ≥ 18 years to ≤ 60 years\n* Clinical indication for a surgical cartilage regeneration procedure\n* Symptomatic grade III\u002FIV cartilage defect according to ICRS or osteochondral defect with a maximum depth of 3 mm\n* A cartilage defect requiring treatment with a defect size of 2-6 cm² on the femoral condyles or patella or trochlea\n* Affected and contralateral knee (if known): Kellgren-Lawrence (K\u002FL) osteoarthritis severity \\\u003C grade III\n* KOOS pain sub-score of ≤ 70 (out of max. 100) in the affected knee joint and \\> 80 (out of max. 100) in the contralateral knee joint measured without taking analgesics within the last 24 hours\n* BMI \\\u003C 35 kg\u002Fm²\n* Written informed consent of the participant, also regarding alternative procedures such as cartilage transplantation (MACT) or matrix-augmented bone marrow stimulation (BMS, AMIC)\n\nExclusion Criteria:\n\n* Clinical indication explicitly for a cartilage regeneration procedure other than the intended study treatment\n* Known varus or valgus malalignment of the affected leg of ≥ 5°\n* Antero-posterior or medio-lateral instability\n* Meniscus loss of more than 20% in the affected compartment\n* Patella instability\n* Simultaneous surgery on other joint structures (cruciate ligament replacement, meniscus suture, partial meniscus resection \\> 20%, osteotomy)\n* Simultaneous higher-grade (ICRS grade III\u002FIV) cartilage damage on the corresponding joint surfaces to the treated cartilage damage (\"kissing lesions\")\n* Osteoarthritis Kellgren-Lawrence (K\u002FL) grade III or IV\n* Arthrofibrosis\n* Metabolic arthropathy\n* Collagenosis\n* Autoimmune disease\n* Tumor disease within the last 5 years\n* Neuromuscular disease\n* Peripheral arterial occlusive disease\n* Intra-articular application of hyaluronic acid or glucocorticoids or platelet concentrates within the last 6 months\n* Joint replacement in the contra-lateral knee or hip within the last 12 months\n* Rheumatoid arthritis or other inflammatory diseases such as autoimmune diseases, seronegative spondyloarthritis, gout, pseudogout\n* Previous fracture in the affected knee joint\n* Osteoporosis\n* Contraindications against the planned operation under general anesthesia\n* Relevant secondary diseases that increase the risk of surgery, e.g. cardiac insufficiency, coronary heart disease, coagulation disorders, diabetes mellitus, liver cirrhosis, renal insufficiency, etc.\n* History of known hypersensitivity to porcine collagens, human albumin, glucose or components of fibrin adhesives used in orthopaedics or surgery\n* Simultaneous participation in another interventional clinical trial (incl. within the last 4 weeks prior to inclusion)\n* Addiction or other illnesses that do not allow the person concerned to assess the nature, scope and possible consequences of the clinical trial (lack of capacity to consent)\n* Indications that the patient is unlikely to adhere to the protocol (e.g. lack of compliance)\n* Persons who are placed in an institution by court or official order\n* Persons who are dependent on the sponsor\n* Pregnant or breastfeeding women\n* Women of childbearing age, except women who meet the following criteria:\n\n  1. Post-menopausal (12 months natural amenorrhea)\n  2. Post-operative (6 weeks after bilateral ovariectomy with or without hysterectomy or bilateral salpingectomy)\n  3. Presence of a negative pregnancy test (urine, not older than 14 days on the day of surgery) and willingness to regularly and correctly use a contraceptive method with a Pearl Index \\\u003C 1 % per year:\n\n     3.1 Combined (oestrogen and progestogen-containing) hormonal contraception 3.2 Hormonal contraception containing progestogens (oral, injected, implanted) 3.3 IUD (hormonal IUD, copper IUD)\n  4. Sexual abstinence\n  5. Vasectomy of the partner",true,"60 Years",{"count":80,"type":20},55,[82,83],"PHASE1","PHASE2","Testing the safety and efficacy of MSC from umbilical cord tissue (UC-MSC) for the treatment of cartilage damage in the knee joint",[27],[87,88,89,90,91],"knee","cartilage","mesenchymal stromal cells","mesenchymal stem cells","UC-MSC","RECRUITING","2026-01-12",{"date":95,"type":34},"2026-01-13",{"date":97,"type":34},"2025-11-10",{"date":99,"type":20},"2028-11",{"name":101,"class":102},"BIONCaRT GmbH","INDUSTRY",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":115,"briefSummary":117,"conditions":118,"keywords":122,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":131,"leadSponsor":133,"locationsCount":42},"100617459","effect-of-agarcollagen-based-compounds-on-osteoarticular-pain-randomized-triple-blind-clinical-trial-100617459","NCT07318896","Effect of Agar\u002FCollagen-based Compounds on Osteoarticular Pain: Randomized Triple-blind Clinical Trial","Evaluation of the Effect of Agar and\u002For Collagen Based Compounds on Osteoarticular Pain. A Randomized, Parallel, Placebo Controlled, Triple Blind Clinical Trial (AGARTROSIS)","AGARTROSIS","Inclusion Criteria:\n\n* Men and women between 40 and 70 years of age.\n* Submit a score of 6 to 10 out of 20 on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) knee pain questionnaire.\n* Sign the informed consent form.\n* Know how to read, write, and speak Spanish and\u002For Catalan.\n\nExclusion Criteria:\n\n* Present body mass index (BMI) values \\\u003C18.5 kg\u002Fm\\^2 or ≥30 kg\u002Fm\\^2.\n* Present intolerances or allergies related to Agar-Agar, or any of the components of the products being evaluated, such as collagen or maltodextrin.\n* Take or have taken medications that may affect the study results. This is especially true for those who have been treated with oral or intra-articular corticosteroids within the 4 and 12 weeks prior to screening, respectively, or medications for osteoarthritis at the time of screening.\n* Patients who depend on prescription medications for pain control.\n* Take multivitamin or mineral supplements, collagen derivatives, or supplements containing bioactive compounds that may exert an anti-inflammatory effect, such as turmeric, ginger, omega-3, or polyphenol supplements.\n\n(Individuals who consume multivitamin, mineral, or collagen-derived supplements or supplements will be eligible to participate in the study, provided they are willing to discontinue their intake for at least two weeks prior to the start of the study and throughout the entire study period).\n\n* Be an active smoker or have been one for less than 6 months.\n* Alcohol consumption:\n\n  * Men: Consume 4 or more Standard Drink Units (SDU) daily or SDUs weekly.\n  * Women: Consume 2 or more Standard Drink Units (SDU)\\* daily or SDUs weekly.\n* Have a diagnosis of osteoarthritis, active rheumatoid arthritis, and any inflammatory arthritic condition such as secondary inflammatory arthritis, gout, pseudogout, knee infection, marked angular deformities, or significant injury to the target joint within the 6 months prior to the start of the trial; arthroplasty and joint surgery of the target knee within the 2 years prior to the start of the study.\n* Have any gastrointestinal disease that affects the absorption of the compound and\u002For the study results, such as celiac disease, Crohn's disease, active cancer of any organ of the digestive or renal system, or hepatitis.\n* Be ineligible to participate in the study, according to the pre-screening evaluator's criteria.\n* Have lost 3 kg or more in the last 3 months.\n* Be pregnant or intend to become pregnant.\n* Be breastfeeding.\n* Be unable to follow the study guidelines.\n* Be participating or have participated in a clinical trial involving drug intervention or nutritional intervention within the last 30 days prior to inclusion in the study.","40 Years","70 Years",{"count":114,"type":20},80,[116],"NA","Joints-comprising bone, cartilage, ligaments, and synovial fluid-enable stable daily movement but may deteriorate with age, excess body weight, overuse, injury, or disease. Such degeneration, common from age 40 onward, underlies joint disorders like osteoarthritis, particularly in the knees, hips, hands, and spine, and is a major cause of chronic pain and disability. While antiinflammatory analgesics remain the standard approach to symptom control, they neither cure disease nor regenerate cartilage and can produce significant long-term adverse effects (gastrointestinal, hepatic, renal, and cardiovascular). These limitations motivate interest in natural or complementary strategies with safer profiles.\n\nWithin this context, marine algae, especially agar derived from red seaweed, have attracted attention for potential intestinal, metabolic, and joint benefits, aided by their fiber content. Another promising option is undenatured type II collagen (UC-II), the principal structural component of articular cartilage, whose endogenous production declines with age; clinical studies indicate that a daily intake of 40 mg UC-II can improve mobility, reduce pain, and enhance quality of life in individuals with osteoarthritis or exercise-related joint discomfort. Based on these considerations, an agar-agar supplement has been developed to relieve knee joint symptoms.",[119,120,121,27],"Osteearthritis","Joint Damage","Inflammation",[123,124,125,126],"Agar-Agar","undenatured collagen type II","Joint pain","knee pain","2025-12-19",{"date":129,"type":34},"2026-01-06",{"date":97,"type":34},{"date":132,"type":20},"2027-02",{"name":134,"class":41},"Fundació Eurecat",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":142,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":21,"phases":145,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":42},"100489979","this-is-a-study-to-evaluate-nanofractures-technique-in-the-treatment-of-cartilage-lesions-100489979","NCT05660161","This is a Study to Evaluate Nanofractures Technique in the Treatment of Cartilage Lesions","A Pilot Study to Evaluate the Functional Outcome of Nanofractures for the Treatment of Cartilage Lesions","Inclusion Criteria:\n\n* Patients with cartilage lesions of the knee scheduled for surgery\n* Age 16-50\n* BMI between 18.5 and 30 points\n* Ability to give informed consent\n\nExclusion Criteria:\n\n* Uncorrected knee instability\n* Meniscectomy \\> 50%\n* Uncorrected knee misalignment\n* Uncontrolled metabolic diseases\n* Inability to give informed consent","16 Years","50 Years",{"count":19,"type":20},[116],"Articular cartilage lesions, with their inherent limited healing potential, remain a challenging problem for orthopaedic surgeons. Various techniques, both palliative and reparative, have been used to treat this injury with variable success rates. If not adequately treated, they may even lead to the development of early-onset osteoarthritis. Among all the available techniques, microfractures are used in restoring the cartilage tissue, especially in the deep and extended lesions.\n\nMore recently, the need for minor bone trauma with still adequate bleeding resulted in the development of nanofractures. Nanofracturing means creating perforations with a smaller diameter that go deeper into the bone while damaging it less. This is supposed to reduce the injury to the subchondral bone and increase the amount of bone marrow-derived mesenchymal stromal cells at the bone surface.\n\nThus, the aim of this pilot study is to evaluate the efficacy of nanofractures for the treatment of cartilage lesions of the knee, specifically focusing on the chondral healing that will be addressed with magnetic resonance imaging.",[27],"2025-08-05",{"date":150,"type":34},"2025-08-06",{"date":152,"type":34},"2023-03-02",{"date":154,"type":20},"2027-01",{"name":156,"class":41},"Ente Ospedaliero Cantonale, Bellinzona",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":164,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":21,"phases":168,"briefSummary":169,"conditions":170,"keywords":176,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":42},"100586437","biopoly-partial-resurfacing-knee-implant-ide-100586437","NCT06915363","BioPoly® Partial Resurfacing Knee Implant IDE","Pivotal, Prospective, Randomized, Controlled, Multicenter Clinical Trial of BioPoly® Partial Resurfacing Knee Implant for Treatment of Focal Cartilage Lesions of the Distal Femur","Inclusion Criteria:\n\n1. Patient is between 30 and 65 years of age25.\n2. KOOS quality of life score ≤ 60.\n3. In the opinion of the Investigator, the patient has the understanding and willingness to comply with all study requirements including the Post-Operative rehabilitation and follow-up protocol.\n4. Patient has cartilage lesion that has failed non-surgical conservative therapy (e,g, anti-inflammatory (NSAID), viscosupplementation, steroid injection, physical therapy, or activity modification) after at least 2 months of beginning the therapy or failed surgical conservative therapy (e.g. debridement\u002Flavage, marrow stimulation, or alignment high tibial osteotomy) that was performed at least 12 months ago in the index knee and is a candidate for surgical intervention.\n5. Patient has cartilage lesion located in the femoral condyle or trochlear facet.\n6. Patient has lesion(s) classified as ICRS grade 2, 3 or 4.\n7. Patient's lesion size may not exceed 3.1 cm2 and must be circumscribed by a 1.5 cm or 2.0 cm diameter circle, or 1.5 cm (M-L) by 2.4 cm (A-P) oval of normal or nearly normal (ICRS grade 0 or 1) cartilage, with an overall depth less than 4mm from the articulating surface.\n8. Patient has subchondral bone quality that is non-osteoporotic and is sufficient to support the implant. The quality of bone will be assessed by the surgeon intraoperatively with a surgical instrument such as an awl.\n\nExclusion Criteria:\n\n1. Patient has body mass index (BMI) ≥ 35.\n2. Patient has autoimmune arthritis, as diagnosed by Investigator.\n3. Patient has advanced degenerative osteoarthritis in index knee (Kellgren-Lawrence Grade 4 and\u002For diagnosed intraoperatively).\n4. Contralateral knee is known to have symptomatic cartilage, meniscal, or ligamentous lesions, generalized osteoarthritis, or requires surgery.\n5. Patient has gout, by Investigator diagnosis or patient-reported history within last 12 months.\n6. Patient has a cartilage lesion that is being treated with a non-surgical conservative therapy (e,g, anti-inflammatory (NSAID), viscosupplementation, steroid injection, physical therapy, or activity modification) and it has been \\\u003C 2 months since beginning treatment or the patient's cartilage lesion has failed surgical therapy (e.g. debridement\u002Flavage, marrow stimulation, alignment (high tibial osteotomy)) in the index knee and it has been \\\u003C 12 months since the surgical treatment.\n7. Patient has a cartilage lesion that is being treated that has failed ACI, OATS or Allograft treatment.\n8. Patient has malalignment of the index knee (\\>5 degrees weight bearing varus or valgus).\n9. Patient has bipolar articular cartilage involvement (or kissing lesions) of the ipsilateral compartment (i.e. greater than ICRS Grade 2 on the opposing articular surface) in the index knee.\n10. Patient has uncorrected ligamentous instability (good joint stability in the index joint with a Grade 1 Lachman or less, no pivot shift for ACL insufficiency and no posterior translation of more than grade 1; no deficits in flexion or extension of \\> 10 degrees compared to contralateral knee) in the index knee.\n11. Patient has undergone a total meniscectomy of index knee.\n12. Patient has undergone patellofemoral arthroplasty of the index knee\n13. Patient currently reports or has a documented history of uncontrolled diabetes.\n14. Patient currently has any condition, therapy, or medication known to impair bone healing.\n15. Patient has had an active systemic infection or joint infection in index knee over the last 12 months.\n16. Patient has an allergy to titanium alloy (Ti-6Al-4V), ultrahigh molecular weight polyethylene (UHMWPE), or hyaluronan\u002F hyaluronic acid (HA).\n17. Patient is pregnant or is planning to become pregnant (for female patients only) at any point during the duration of the study.\n18. Patient has legal involvement or any other issue that would hinder completion of the two-year follow-up period.\n19. Patient is participating in other studies and\u002For receiving any other simultaneous therapy in index knee.\n20. Patient has an uncorrected tear of the meniscus of the index knee. (Partial meniscectomy that retains \\>50% of the meniscus is allowed prior to or concurrently with the cartilage treatment procedure. Meniscus suture repair is allowed prior to or concurrently with the cartilage treatment procedure if \\>50% of the functional meniscus remains.).\n21. Patient has an additional cartilage lesion(s) (ICRS Grade 3 or 4) in the index knee, located on the patella, trochlea, tibia, or non-weight bearing area of index condyle that requires treatment.\n22. More than one implant is required to accommodate defect in the index knee.\n23. Patient has inadequate bone stock (e.g., cysts, osteoporosis) underlying the lesion site as determined intra-operatively by the investigator\n\n    1. As determined by the investigator through use of an awl or a similar instrument to determine if the bone quality is insufficient to support the BioPoly device.\n    2. If the cause of inadequate bone stock is due to cysts or to the boney portion of an osteochondral lesion being excessive, then the investigator may opt to fix the implant with cement rather than exclude the patient for inadequate bone stock.\n24. Patients with osteoporosis, osteopenia, Paget's disease, osteomalacia or any other metabolic bone disease; a. Osteoporosis is defined as Simple Calculated Osteoporosis Risk Estimation (SCORE) above 6 and DXA T-score \\\u003C -2.5 or QCT T-score \\\u003C 80mg\u002Fcubic cm. History of a fragility fracture requires that a DXA scan or QCT scan is completed","30 Years","65 Years",{"count":167,"type":20},152,[116],"The goal of this randomized controlled clinical trial is to demonstrate the safety and effectiveness of the BioPoly® Partial Resurfacing Knee Implant for the treatment of cartilage defects of the distal femur in adult patients with knee pain and symptoms who are candidates for surgical intervention of the knee compared to outcomes for the control group.\n\nThe primary effectiveness endpoint is Month 24 composite clinical success (CCS) defined by:\n\n* no secondary surgical intervention (SSI) and\n* an improvement from baseline in the Knee injury and Osteoarthritis Outcome Score (KOOS) total score (scaled 0 to 100) of at least 10 points.\n\nResearchers will compare the CCS for the investigational device group to a control group receiving the standard of care, either microfracture or debridement).\n\nSubjects randomized to the investigational group will receive the BioPoly Knee device and those randomized to the control group will receive the current standard of care, either microfracture or debridement.",[171,172,27,173,174,175],"Knee Pain Chronic","Knee Osteoarthritis","Cartilage Defects of the Knee","Cartilage or Osteochondral Defects in the Knee","Cartilage Lesion",[177,178,179,180],"articular cartilage","cartilage lesion","focal cartilage defect","cartilage defect","2025-04-15",{"date":183,"type":34},"2025-04-17",{"date":185,"type":34},"2025-03-17",{"date":187,"type":20},"2028-12",{"name":189,"class":102},"BioPoly LLC",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":164,"maxAge":78,"enrollmentInfo":197,"targetDuration":4,"studyType":21,"phases":199,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":42},"100417473","prospective-study-the-effect-on-clinical-outcome-after-treatment-of-mtp-cartilage-lesions-in-hallux-valgus-surgery-100417473","NCT04716140","Prospective Study: The Effect on Clinical Outcome After Treatment of MTP Cartilage Lesions in Hallux Valgus Surgery","Prospective Study: The Effect on Clinical Outcome After Treatment of MTP Cartilage Lesions","Inclusion Criteria:\n\n* hallux valgus\n\nExclusion Criteria:\n\n* younger than 30 years, older than 60 years\n* extra pathologies other than hallux valgus",{"count":198,"type":20},99,[116],"The aim of this study is to investigate the point or nonsense of treating cartilage lesions at the level of the first metatarsophalane joint. To date, no clear guidelines have been found in the literature with regard to the treatment of cartilage lesions at the MTP I joint during corrective surgery for hallux valgus, nor has it been investigated whether this can have an effect on the clinical outcome.",[202,27],"Hallux Valgus","2025-03-10",{"date":205,"type":34},"2025-03-12",{"date":207,"type":34},"2020-09-15",{"date":209,"type":20},"2026-12-31",{"name":211,"class":41},"Tom Lootens"]